Patients undergoing treatment with immunosuppressant drugs following solid organ or hematopoietic stem cell transplantation are at particular risk for development of serious infections such as invasive aspergillosis. Four triazole antifungal drugs, voriconazole, posaconazole, itraconazole, and isavuconazole, are approved to treat invasive aspergillosis either as first-or second-line therapy. All of these agents are inhibitors of cytochrome P450 3A4, which plays a key role in metabolizing immunosuppressant drugs such as cyclosporine, tacrolimus, and sirolimus. Thus, co-administration of a triazole antifungal drug with these immunosuppressant drugs can potentially increase plasma concentrations of the immunosuppressant drugs, thereby resulting in toxicity, or upon discontinuation, inadvertently decrease the respective concentrations with increased risk of rejection or graft-versus-host disease. In this article, we review the evidence for the extent of inhibition of cytochrome P450 3A4 by each of these triazole antifungal drugs and assess their effects on cyclosporine, tacrolimus, and sirolimus. We also consider other factors affecting interactions of these two classes of drugs. Finally, we examine recommendations and strategies to evaluate and address those potential drug-drug interactions in these patients. Invasive aspergillosis (IA) is the most common IFD in HSCT recipients and has been reported to account for between 40% and 60% of cases. 4, 5 In SOT recipients, IA is the second most common IFD overall, but the leading IFD in lung transplant recipients. 6 Mortality from IA is substantial in both patient populations. In prospective, multicenter, observational studies, the overall 6-week mortality rate among HSCT recipients with IA in North America was 22% 5 and 1-year mortality rate in the United States (US) was 75%. 4 In a separate prospective, multicenter, observational study, the 1-year mortality rate among SOT
recipients in the US was 41%.
2 Triazole antifungal agents help to fill an important need for efficacious treatments to reduce mortality in these patients.
Triazole antifungal agents have emerged as an important class of drug to treat and prevent IA. 3 Currently, four triazole antifungal agents have a labeled indication that includes treatment or prevention of IA in the US and/or European Union (EU). Voriconazole is available as oral (tablet or oral solution) and intravenous (IV) formulations and is approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of IA in adults and children (FDA, aged ≥12 years; EMA, aged ≥2 years) and the prevention of IFDs (including IA) in HSCT patients (EMA only).
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Posaconazole is available as an IV formulation, an oral suspension, or as delayed-release tablets. It is approved by the FDA (patients aged 13 years and older) and EMA (patients aged 18 years and older) as antifungal prophylaxis in patients who are at high risk of developing infections because of being severely immunocompromised, such as
HSCT recipients with graft-versus-host disease or those with hematologic malignancies with chemotherapy-induced prolonged neu-
; it is also approved by the EMA for the treatment of adult patients with IA when amphotericin B or itraconazole cannot be tolerated or has failed. 10 Itraconazole is available in the US as an oral solution or capsules (although IV formulations are available in some other countries) and is approved by the FDA for the treatment of IA in patients intolerant or refractory to amphotericin B. 11 It was approved for use in Europe in the early 1990s, prior to the formation of the EMA, and so labeling information (including indications) is countryspecific. Isavuconazonium sulfate, the prodrug of isavuconazole (hereafter referred to as isavuconazole throughout, with dosing expressed throughout as isavuconazole equivalents), is available as oral and IV formulations and is approved by the FDA and EMA for the treatment of adult patients with IA.
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Transplant recipients are required to take immunosuppressant drugs such as cyclosporine, tacrolimus, sirolimus, or everolimus to prevent graft-versus-host disease or organ rejection; therefore, consideration must be given to potential interactions between immunosuppressive and antifungal agents. 14 The cytochrome P450 3A4 (CYP3A4) pathway plays an important role in the metabolism of these immunosuppressant drugs. 15 Because all triazole antifungal agents approved for the management of IA inhibit CYP3A4 to various degrees, and all except posaconazole are also substrates for CYP3A4 (although each has different substrate affinity), 16 this pathway is a highly relevant potential point of drug-drug interactions in clinical practice.
CYP3A4 plays a key role in the metabolism and bioavailability of cyclosporine, tacrolimus, sirolimus, and everolimus (together with CYP3A5, the efflux transporter P-glycoprotein [P-gp], and CYP2C8 [everoli-
mus only], discussed in more detail in later sections). [17] [18] [19] An antifungal treatment that strongly inhibits CYP3A4 will, therefore, increase plasma concentrations of these immunosuppressant agents. CYP3A
enzymes are present in the small intestine and liver, 20 and so the route of administration of immunosuppressive drugs is also a key factor that requires consideration when these classes of drugs are used concomitantly. Whereas both intestinal and hepatic enzymes would be major sites of interaction during oral administration, interactions via hepatic CYP3A enzymes would predominate during IV administration.
Increases in plasma concentration of immunosuppressive drugs can result in adverse effects. For example, elevated serum concentrations of both cyclosporine and tacrolimus are potentially nephrotoxic and neurotoxic, 21 whereas sirolimus, everolimus, and cyclosporine have been associated with pulmonary toxicity. 22, 23 Furthermore, the extent of immunosuppression (eg, high blood concentrations or use of more than one immunosuppressant agent) has been demonstrated in some SOT patients to be associated with an increased risk for the development of late infections. 24, 25 In addition, intra-patient variability in tacrolimus exposure is associated with an increased risk of acute rejection. 26 In a recent retrospective database analysis of patients from 150
US hospitals between 2005 and 2013, tacrolimus was identified as one of the top 25 drugs for which interactions with both voriconazole and itraconazole were reported in hospitalized patients.
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In this article, we review the inhibitory potential of CYP3A4 activity by the triazoles used to treat IA, as illustrated by their effects on the pharmacokinetics of midazolam, a pure CYP3A4 substrate. We then review the interaction profiles of these triazoles with cyclosporine, tacrolimus, and sirolimus as models for immunosuppressant drugs metabolized by CYP3A4 for which interactions with triazole antifungal agents have been best characterized. Finally, we briefly review available evidence for other immunosuppressant agents and examine other factors that require consideration with respect to interactions of these two classes of drugs.
| INHIBITION OF CYP3A4 BY TRIAZOLE ANTIFUNGAL AGENTS: MIDAZOLAM PHARMACOKINETICS AS A PROBE FOR CYP3A4 ACTIVITY
Midazolam is an anxiolytic benzodiazepine that is a sensitive in vivo substrate of CYP3A4 and is recommended by the FDA and EMA as a probe to classify whether a drug is an inhibitor of CYP3A4. orally after the last of four daily doses of 100 mg oral itraconazole was increased almost 6-fold and the C max was increased approximately 2.5-fold. 35 In a third open-label study in nine healthy subjects, the AUC 0-∞ of midazolam following a 7.5 mg oral dose increased 8-fold when administered 2 hours after oral itraconazole 100 mg QD and 2.6-fold when administered 4 days after the last dose of itraconazole. 36 The AUC 0-19 h ratio of α-hydroxymidazolam to midazolam was also significantly decreased (P < .005), although the extent of the decrease was not reported. A fourth study assessed the effects of itraconazole on both oral and IV midazolam in a randomized, doubleblind, crossover study in 12 healthy volunteers. 37 Figure 1D ). In addition, co-administration with isavuconazole was associated with a 1.7-fold increase in the C max of midazolam and its t 1/2 was prolonged by 60%. The AUC 0-∞ ratio of α-hydroxymidazolam to midazolam was decreased by approximately one-third, from 0.33 to 0.20, although no statistical test of this difference was performed.
As discussed above, the FDA provides categorization of the relative strength of CYP inhibitors according to their effects on recognized substrates based on study results provided to them by the pharmaceutical companies. 40 As per those criteria, voriconazole, posaconazole, and itraconazole are all considered strong inhibitors of CYP3A isoenzymes (≥5-fold increases in midazolam AUC), whereas isavuconazole is con- 
| EFFECTS OF TRIAZOLE ANTIFUNGALS ON THE PHARMACOKINETICS OF CYCLOSPORINE, TACROLIMUS, AND SIROLIMUS
Consistent with their inhibitory effects on CYP3A4, all of these triazoles have been demonstrated to increase the exposure of coadministered cyclosporine, tacrolimus, and sirolimus. Nevertheless, the potency of inhibition for each of voriconazole, itraconazole, posaconazole, and isavuconazole varies with respect to these immunosuppressant drugs.
| Voriconazole
Studies and prescribing information indicate that concurrent administration of voriconazole increases the exposure concentrations of these immunosuppressant drugs modestly or markedly (Table 1 7,8,10-13, [42] [43] [44] [45] [46] [47] ).
In seven kidney transplant recipients who completed a randomized, double-blind, placebo-controlled, crossover study, 7.5 days of oral voriconazole administration (200 mg BID) increased the AUC for the dosing interval (AUC 0-τ ) of oral cyclosporine (150-375 mg/day) by 1.7-fold. 42 In an analysis of 21 HSCT recipients, initiation of voriconazole treatment (oral or IV) was also found to increase the concentration/dose ratio of cyclosporine from 86.0 to 120.2 and that of tacrolimus from 595.9 to 890.7. 48 However, others have reported that the effects of voriconazole on cyclosporine or tacrolimus concentrations may be highly variable and may not be related to plasma con- The effects of posaconazole on sirolimus exposure were assessed in a study of 12 healthy subjects. 44 Compared with 2 mg sirolimus T A B L E 1 Quantitative effects of triazole antifungals on exposure of immunosuppressants cyclosporine, sirolimus, and tacrolimus. (Adapted from Groll et al. alone, co-administration with posaconazole after 16 days at 400 mg BID increased the C max and AUC of sirolimus by 6.7-fold and 8.9-fold, respectively. In a retrospective analysis of 15 HSCT recipients who received sirolimus (median dose 2 mg/day), 14 of whom also received tacrolimus (median dose 2.3 mg/day), posaconazole was initiated as prophylaxis or treatment of IFD for a median of 78 days. 55 
| Itraconazole
Available data indicate that itraconazole markedly increases the exposure of all three immunosuppressant drugs (Table 1) . Three small stud- 
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In a third open-label study in 16 HSCT recipients treated with either cyclosporine or tacrolimus (n = 8 each), itraconazole (oral solution) was administered at 200 mg BID for 2 days, then QD from 30 to 100 days after transplantation. 46 Exposure was not reported in this study, but after 7 days of co-administration, the dose-adjusted blood concentra- ; FDA prescribing information also indicates this effect, but no quantitative information is provided. 
| Isavuconazole
Information on the effects of isavuconazole on these immunosuppressant drugs is derived from three clinical studies in healthy adults (cyclosporine 300 mg, n = 24; tacrolimus 5 mg, n = 24; sirolimus 2 mg, n = 22) 47 (Table 1 ). In each of these studies, isavuconazole was administered as 200 mg TID for 2 days, then 200 mg QD thereafter.
Co-administration of isavuconazole increased the AUC 0-∞ and C max of cyclosporine 1.3-fold and 1.1-fold, respectively, whereas increases with tacrolimus were in 2.3-fold and 1.4-fold, respectively, and increases with sirolimus were 1.8-fold and 1.7-fold, respectively. These data are also contained in EMA prescribing information for isavuconazole, 13 although FDA prescribing information only mentions an approximately 2-fold increase of tacrolimus and sirolimus. 12 
| Relative impact on co-administered immunosuppressant drugs
Comparisons between the effects of these triazoles on the pharmacokinetics of immunosuppressant drugs must be made with caution because no head-to-head studies have been conducted. Moreover, the subjects included in each study were not necessarily comparable (eg, transplant recipients vs healthy subjects), not all studies tested the approved clinical dosing regimen, and in many cases, the avail- 
| Other factors requiring consideration
Although interactions of these three immunosuppressant drugs with triazole antifungal drugs are the most studied, other immunosuppressive drugs are available and so their interactions need to be considered. As also mentioned above, everolimus is metabolized by CYP3A4
and it is also a substrate for the efflux transporter P-gp (see below).
Although interactions of everolimus with triazole antifungal agents
have not been systematically studied, case reports and retrospective analyses have described dramatic increases in everolimus concentrations and associated adverse effects when administered with voriconazole or posaconazole. [60] [61] [62] [63] Synthetic corticosteroids are commonly used to treat a variety of inflammatory conditions, and the metabolism of most or all involves CYP3A isoenzymes. [64] [65] [66] However, interpretation of CYP3A-mediated drug-drug interactions may be complicated because those agents in turn can affect the expression of CYP genes via effects on the glucocorticoid receptor. 67 Nevertheless, one study reported a 2.5-fold increase in the AUC 0-24 h of oral methylprednisolone (single 48 mg dose) when co-administered with itraconazole (400 mg on Day 1, then 200 mg QD for 3 days), 68 and labeling of voriconazole indicates that co-administration with prednisone (the prodrug of prednisolone) increases the AUC 0-∞ prednisolone by 34%.
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On the other hand, isavuconazole (200 mg TID for 2 days, then 200 mg QD thereafter) had little effect on prednisolone following a single 20 mg dose of prednisone (AUC 0-∞ increased 8%). 47 Notwithstanding the importance of the direct effects of triazole antifungal agents on CYP3A4, their interactions may also involve other metabolic pathways, and the unique pharmacokinetic properties of each agent are also a factor that should be considered. For example, voriconazole is primarily metabolized by CYP2C19, with contributions by CYP3A4 and CYP2C9. 7, 8 Voriconazole exhibits non-linear pharmacokinetics such that exposure increases disproportionately with increasing dosages. 69 That may be due in part to saturable metabolism, 70 although more recent evidence suggests that it may instead (or in addition) be related to dose-dependent autoinhibition of CYP3A4 activity. 71 In any event, considerable inter-and intra-subject variability in plasma concentrations of voriconazole has been observed and is at least partly due to allelic variants of the CYP2C19 gene that confer reduced or enhanced enzyme activity in subjects characterized as poor or extensive/ultra-rapid metabolizers, respectively. 72 At a given dose of voriconazole, clearance in poor metabolizers is reduced, thus resulting in increased plasma concentrations of voriconazole. In turn, this could potentially lead to adverse effects, including elevated concentrations of immunosuppressant drugs metabolized by CYP3A4.
The same dose in extensive or ultra-rapid metabolizers would result in lower plasma concentrations of voriconazole that would be less likely to affect CYP3A4-mediated metabolism but may not be sufficient to confer therapeutic benefit.
Uptake and efflux transporters can also influence the pharmacokinetics of drugs as they have the potential to alter their distribution and/or clearance. Given that most immunosuppressive agents are also substrates of the P-gp efflux transporter, effects of triazole antifungal drugs on P-gp are also an important clinical consideration.
Voriconazole does not appear to have any effect on P-gp-mediated transport of N-methyl-quinidine (NMQ) transport in vitro 73 or P-gpmediated digoxin transport in vivo. 74 In contrast, posaconazole and itraconazole both strongly inhibit NMQ transport in vitro (IC 50 , 3 μM and 2 μM, respectively) 73 and increase plasma concentrations of digoxin in vivo (posaconazole, extent of increase not specified; itraconazole, 80% increase of serum digoxin concentration for 0.25 mg QD digoxin with 200 mg oral itraconazole vs placebo for 10 days).
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The effect of isavuconazole on P-gp is not as clear. Furthermore, plasma exposure of digoxin in vivo was only increased by ~25% with co-administration of the clinically recommended dose of isa vuconazole, and a 37% increase in AUC 0-∞ of the P-gp substrate atorvastatin with co-administered isavuconazole was mostly explicable in terms of its moderate inhibition of CYP3A4. 76 On the other hand, the increase in digoxin exposure was unlikely to result from inhibition of CYP3A4 as this enzyme has at most only a minor role in digoxin metabolism, 77 and so some of the effect of isavuconazole on atorvastatin exposure may well have resulted from P-gp inhibition. Nevertheless, these observations suggest that isavuconazole is a weak inhibitor of 8 whereas that of posaconazole is independent of dose at 27 hours. 9 The terminal half-life for itraconazole capsules is 32-48 hours with repeated doses, 11 although the terminal half-lives of itraconazole and the hydroxyitraconazole metabolite for at least one IV formulation are dose-dependent and can extend beyond 150 hours.
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The terminal half-life of isavuconazole is independent of dose at 130 hours. 12 Thus, any drug-drug interaction involving these triazole antifungal agents might be expected to persist for a longer duration with isavuconazole or some IV formulations of itraconazole compared with either voriconazole or posaconazole. In the case of isavuconazole, its effects on CYP3A4 in vitro involves both inhibition (an effect mediated by direct interactions of the proteins, and so requiring presence of the inhibitor) and induction 39, 83 (an effect on gene expression that can persist after the inducer is eliminated). If this is also true in vivo, this may account for the weaker inhibition of CYP3A4 by isavuconazole compared with the other triazole antifungal agents. Thus, any CYP3A4-mediated drug-drug interaction with isavuconazole could potentially be biphasic in nature during cessation of treatment.
| Current recommendations and strategies to address drug-drug interactions
The interactions of triazoles reviewed above with cyclosporine, tacrolimus, and sirolimus have required accompanying recommendations in product labeling. Both FDA and EMA labeling for these triazole antifungal drugs are largely consistent, and unless otherwise indicated, the discussion points below apply to both.
Labeling for voriconazole emphasizes that increased concentrations of cyclosporine and tacrolimus have been associated with nephrotoxicity, and so patients should be monitored for the development of abnormal renal function. 7, 8 Empirical dose reductions are recommended for both cyclosporine (reduce to one-half) and tacrolimus (reduce to one-third) when initiating treatment with voriconazole, and
concentrations of cyclosporine or tacrolimus should be carefully monitored during and after cessation of treatment. As mentioned above, concurrent use of voriconazole with sirolimus is contraindicated.
Labeling for posaconazole also cautions about nephrotoxicity associated with elevated concentrations of cyclosporine (EU) 10 or both cyclosporine and tacrolimus (US). 9 Labels do not mention monitoring renal function in that context, although it would seem a reasonable measure.
When initiating treatment with posaconazole, empirical dose reductions are recommended for both cyclosporine (reduce to three-quarters) and tacrolimus (reduce to one-third). As with the recommendations for voriconazole, frequent monitoring of cyclosporine or tacrolimus concentrations is also recommended during and at discontinuation of posaconazole treatment so that the dose can be adjusted accordingly.
Concurrent use of posaconazole with sirolimus is contraindicated in FDA labeling, and although not contraindicated in the EMA label, a recommendation for very frequent monitoring of trough concentrations of sirolimus is included for instances in which it may be unavoidable.
As discussed above, approval for itraconazole was obtained prior to the formation of the EMA, and so labeling is not provided by the EMA but rather by individual country members of the EU. In FDA labeling, a "use with caution" warning is included for cyclosporine, tacrolimus, and sirolimus, which includes suggestions to monitor for signs and symptoms of side effects and to consider dose reductions. 11 The label does not mention therapeutic drug monitoring, although that would seem prudent.
Labeling for isavuconazole in the US also includes a "use with caution" warning for cyclosporine, tacrolimus, and sirolimus, and mentions the possibility of serious side effects in the kidney or brain associated with elevated concentrations of these immunosuppressant drugs.
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Neither US or EU labeling recommends empirical dose reductions of any of these immunosuppressant drugs when initiating isavuconazole treatment, but both recommend that their concentrations be monitored and adjusted as needed. 12, 13 Recommendations from medical societies regarding co- recommended to obtain serum trough concentrations for both the triazole antifungal drugs (voriconazole, posaconazole, itraconazole, and possibly isavuconazole) and any potentially interacting drugs, which includes cyclosporine, tacrolimus, and sirolimus. 86 Recently, a six-step strategy was recommended to evaluate and respond to the potential for drug-drug interactions of triazole antifungal agents with immunosuppressant drugs. 87 The first step involves prediction of such interactions based on the underlying pharmacologic mechanisms using resources such as the summary of product characteristics or drug compendia. Second, the identification of any interac- 
